AKERO THEREP.INC.DL-0001
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunct… Read more
AKERO THEREP.INC.DL-0001 (0K4) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, AKERO THEREP.INC.DL-0001 (0K4) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AKERO THEREP.INC.DL-0001 - Net Assets Trend (None–None)
This chart illustrates how AKERO THEREP.INC.DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AKERO THEREP.INC.DL-0001 (None–None)
The table below shows the annual net assets of AKERO THEREP.INC.DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AKERO THEREP.INC.DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AKERO THEREP.INC.DL-0001 Competitors by Market Cap
The table below lists competitors of AKERO THEREP.INC.DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fastly Inc. Cl A
LSE:0A3P
|
$3.35 Billion |
|
Prada S.p.A
PINK:PRDSF
|
$3.35 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
$3.35 Billion |
|
Hanwha Solutions
KO:009830
|
$3.35 Billion |
|
Gjensidige Forsikring ASA
OTCGREY:GJNSF
|
$3.35 Billion |
|
Shenzhen H&T Intelligent Control Co Ltd
SHE:002402
|
$3.35 Billion |
|
Beijing Roborock Technology Co Ltd
SHG:688169
|
$3.35 Billion |
|
Muthoot Finance Limited
NSE:MUTHOOTFIN
|
$3.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AKERO THEREP.INC.DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AKERO THEREP.INC.DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AKERO THEREP.INC.DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AKERO THEREP.INC.DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AKERO THEREP.INC.DL-0001 (0K4) | €- | N/A | N/A | $3.35 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |